Pulse Biosciences (PLSE)Chief Commercial Officer sold ~$7.4K

~$7.4K

Approx. value · 400 sh @ $18.48

43K

Holds after · shares reported

Traded

Sep 19, 2025

Filed

Sep 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 11, 2024InsiderDirector purchased ~$189K of PLSE shares in the open market
2. Sep 12, 2024InsiderDirector purchased ~$2.09M of PLSE shares in the open market
3. Sep 10, 2025InsiderDirector purchased ~$508K of PLSE shares in the open market
4. Sep 11, 2025InsiderDirector sold ~$370K of PLSE shares in the open market
5. Sep 12, 2025InsiderDirector sold ~$358K of PLSE shares in the open market
6. Sep 15, 2025InsiderDirector sold ~$394K of PLSE shares in the open market
7. Sep 16, 2025InsiderDirector sold ~$407K of PLSE shares in the open market
8. Sep 17, 2025InsiderDirector sold ~$324K of PLSE shares in the open market
9. Sep 18, 2025InsiderOfficer sold ~$370K of PLSE shares in the open market
10. Sep 19, 2025 · this disclosureInsiderOfficer sold ~$7.4K of PLSE shares in the open market

What came next

1. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
2. Jan 8, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On January 8, 2026, the Board of Directors (the “Board”) of Pulse Biosciences, Inc. (the “Company”) elected Maria Sainz to the Board, effective immediately. Ms. Sainz will serve until her term expires at the annual meeting of stockholders to be held in 2026 and until her successor is elected and qualified or until her earlier death, resignation or removal.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pulse Biosciences

OQRO holds no insider, Congress, fund or contract record for Pulse Biosciences dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PLSE page.

Other recent filings by Kevin Patrick Danahy, Chief Commercial Officer

• SEC Form 4 at Pulse Biosciences (PLSE)Sep 23, 2025

The full history of Kevin Patrick Danahy, Chief Commercial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pulse Biosciences

• SEC Form 4Sep 23, 2025
• SEC Form 4Sep 19, 2025
• SEC Form 4Sep 19, 2025
• SEC Form 4Sep 16, 2025
• SEC Form 4Sep 16, 2025
• SEC Form 4Sep 16, 2025

Everything OQRO holds on this company is on its PLSE page.